San Diego-based Viking Therapeutics marked by itself as a significant competitor while in the weight loss drug current market in February following revealing promising information from a mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when specified being a weekly injection and in Mar